Thalassemia Surgery in India and UAE | Complete Patient Guide

• CONFIRMED ELIGIBILITY:

• Diagnosis of transfusion-dependent beta-thalassaemia major or severe thalassaemia intermedia confirmed by HPLC (High-Performance Liquid Chromatography), haemoglobin electrophoresis, and molecular mutation analysis (e.g., IVS1-5, IVS1-1, codon 41/42, codon 8/9 mutations)

• Pesaro Class I or II status (preferred); selected Class III patients considered at specialized centers with RTC regimens

• Age: Paediatric patients (2–16 years) have highest cure rates; adult transplant (up to 40 years) feasible at experienced centers with RTC or haploidentical protocols

• Availability of a suitable donor: matched sibling donor (MSD, 10/10 HLA match — gold standard, ~85–92% cure rate), matched unrelated donor (MUD, 10/10 or 9/10), or haploidentical family donor (parent/sibling, 5/10, with PTCy protocol)

• Adequate organ function: LVEF ≥50% on 2D-ECHO, ALT/AST <5× ULN, serum bilirubin <2× ULN, creatinine clearance >60 mL/min/1.73m²

• Cardiac MRI T2* >10 ms (severe myocardial siderosis [T2* <10 ms] requires pre-transplant intensive chelation with Deferoxamine ± Deferiprone combination to reduce cardiac iron burden before conditioning)

• Liver MRI R2* quantification and liver biopsy (if indicated) to stage hepatic iron and fibrosis

• REQUIRED PRE-TRANSPLANT DIAGNOSTICS:

• Complete blood count with reticulocyte count and peripheral smear

• Haemoglobin HPLC and molecular mutation panel (both patient and parents)

• HLA typing (high-resolution 10-locus) of patient and all available family members (siblings, parents, children if applicable)

• Ferritin, serum iron, TIBC, transferrin saturation

• Liver MRI R2* (liver iron concentration) and cardiac MRI T2* (myocardial iron)

• Liver function tests, renal function, thyroid function (TSH, Free T4), fasting glucose, cortisol, LH, FSH, testosterone/oestradiol (endocrine panel)

• 2D-Echocardiography with Doppler (baseline cardiac function)

• Pulmonary function tests (spirometry, DLCO) — for patients >5 years

• Virology screen: HIV, HBsAg, Anti-HCV, CMV IgG/IgM, EBV, HSV, VZV, Toxoplasma (patient and donor)

• Bone marrow trephine biopsy (to assess marrow architecture and degree of extramedullary haematopoiesis)

• Chest X-ray and abdominal ultrasound with spleen size measurement

• CONTRAINDICATIONS:

• Uncontrolled systemic infection at time of conditioning

• Severe, irreversible hepatic cirrhosis (Ishak fibrosis score 5–6 without reversibility; relative contraindication, individualized assessment)

• LVEF <40% refractory to chelation therapy

• Prior malignancy within 5 years (non-melanoma skin cancer excepted)

• HIV-positive status (relative contraindication; specialist HIV-BMT programs may accept selected patients)

• No suitable donor identified after exhausting sibling, MUD, and haploidentical options

• Patient/family non-compliance with post-transplant immunosuppression and monitoring protocol (strict adherence required for 12–24 months post-transplant)

STANDARD MYELOABLATIVE CONDITIONING (MAC) — GOLD STANDARD FOR CLASS I–II PATIENTS:

The most widely used preparative regimen for thalassaemia transplant is Busulfan + Cyclophosphamide ± Thiotepa (Bu-Cy ± Thio). Intravenous Busulfan is now preferred over oral dosing due to superior pharmacokinetic predictability; therapeutic drug monitoring (TDM) targets an AUC of 900–1,350 µmol·min/L per dose to balance marrow ablation against hepatic sinusoidal obstruction syndrome (SOS/VOD) risk. Cyclophosphamide is administered at 200 mg/kg (total) over 4 days. Thiotepa (10 mg/kg) is added in many protocols to improve stem cell engraftment in hypercellular, hyperactive thalassaemic marrows. Hydroxyurea preconditioning (beginning 3–6 months pre-transplant) and azathioprine are used in some protocols (the Pesaro/Lucarelli protocol) to suppress haematopoiesis and reduce graft rejection risk.

REDUCED-TOXICITY CONDITIONING (RTC) — FOR CLASS III, OLDER, OR COMORBID PATIENTS:

Treosulfan (42 g/m² total over 3 days) combined with Fludarabine (150 mg/m² over 5 days) and Thiotepa (10 mg/kg) constitutes the contemporary RTC backbone. Treosulfan is a bifunctional alkylating agent with proven myeloablative potency but a significantly more favourable hepatotoxicity and mucositis profile than Busulfan, making it the preferred platform for patients with liver iron overload, older children, or adults with organ compromise. Published data demonstrate 80–86% thalassaemia-free survival with Treosulfan-based RTC in Class III patients, a population historically facing >30% transplant-related mortality with MAC.

HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCy):

For the 30–40% of patients who lack an HLA-matched sibling and cannot identify a MUD through international registries, haploidentical transplantation (using a parent, half-matched sibling, or child) with PTCy (50 mg/kg on Days +3 and +4 post-transplant) has become a viable curative pathway. PTCy selectively eliminates alloreactive T-cells responsible for both GvHD and graft rejection while preserving regulatory and memory T-cells. Indian centers have published prospectively on haploidentical thalassaemia transplant with cure rates of 70–78%, representing a transformative option for resource-limited settings where donor registries are under-represented. T-cell receptor alpha/beta (TCRαβ) and CD19 depletion of the graft using the CliniMACS Prodigy platform (Miltenyi Biotec) is an advanced alternative graft manipulation strategy offering highly selective T-cell depletion for haploidentical and MUD transplants, reducing GvHD without compromising engraftment.

STEM CELL SOURCE OPTIONS:

• Bone Marrow (BM): Historically preferred in thalassaemia; lower chronic GvHD rates versus PBSC

• Peripheral Blood Stem Cells (PBSC): Faster engraftment but higher chronic GvHD risk; used selectively

• Umbilical Cord Blood (UCB): Used in selected paediatric patients with very small body weight (<20 kg) when a cord unit with adequate cell dose (>5×10⁷ TNC/kg) is available from a accredited public cord blood bank

GVHD PROPHYLAXIS REGIMENS:

• MSD: Ciclosporin A (CyA) + short-course Methotrexate (MTX Days +1, +3, +6, +11)

• MUD: CyA + MTX + Anti-Thymocyte Globulin (ATG, Thymoglobulin® 4.5 mg/kg or ATG-Fresenius® 60 mg/kg)

• Haploidentical: PTCy + CyA + MMF ± Sirolimus

IRON OVERLOAD MANAGEMENT (CONCURRENT WITH TRANSPLANT PLANNING):

All candidates undergo aggressive iron chelation optimization before transplant. Combination chelation with Deferoxamine (subcutaneous infusion, 40–60 mg/kg/night, 5–7 nights/week) plus Deferiprone (75–100 mg/kg/day orally, with monthly absolute neutrophil count monitoring) is the standard for patients with cardiac T2* <20 ms. Deferasirox (20–35 mg/kg/day, oral dispersible tablet or film-coated tablet) is an alternative monotherapy for patients with hepatic iron predominance. Post-transplant, chelation is typically resumed at Day +60–100 if ferritin remains >1,000 ng/mL and discontinued once iron stores normalize (usually by 12–24 months, facilitated by therapeutic phlebotomy once haematological engraftment is robust).

EMERGING & INVESTIGATIONAL APPROACHES (AVAILABLE AT SELECT CENTERS):

• Gene Therapy (Betibeglogene Autotemcel / LentiGlobin): FDA/EMA-approved for transfusion-dependent thalassaemia without a matched sibling donor; available at select UAE centers (Cleveland Clinic Abu Dhabi, investigational access). Involves autologous HSC collection, ex-vivo lentiviral transduction with a functional beta-globin gene, and reinfusion after myeloablative conditioning. Eliminates GvHD risk entirely but costs $1.8–2.5 million USD and is not yet available in India through standard pathways.

• Luspatercept (Reblozyl®): Activin receptor ligand trap approved for non-transfusion-dependent thalassaemia and as post-transplant supportive therapy; reduces ineffective erythropoiesis and transfusion burden in the peri-transplant period in selected protocols.

PHASE 1 — PRE-TRAVEL ASSESSMENT (Weeks -12 to -8 before transplant admission): GAF Healthcare coordinates remote case evaluation: medical records, mutation reports, HLA typing results, ferritin trends, organ function data, and existing chelation history are reviewed by the destination transplant team. A formal eligibility report is issued within 5–7 working days. Concurrently, HLA typing of all available family members is initiated or reviewed to identify the optimal donor category (MSD > MUD > Haploidentical). Iron overload optimization begins or intensifies: target ferritin <2,500 ng/mL and cardiac T2* >10 ms before conditioning. Chelation protocol is adjusted as needed.

PHASE 2 — ARRIVAL & PRE-TRANSPLANT WORKUP (Days -21 to -8): Patient and family (including donor, if sibling MSD) arrive in India or the UAE. GAF Healthcare coordinates airport reception, accommodation placement within a 2 km radius of the transplant center, and SIM/translator services. Over 7–10 days, the full pre-transplant diagnostic battery is repeated in-country to confirm current organ status: 2D-ECHO, cardiac MRI T2*, liver MRI R2*, PFTs, virology, HLA re-confirmation, and bone marrow biopsy if required. Donor undergoes independent medical assessment and donation fitness workup. Informed consent is obtained by the transplant physician in the patient's language.

PHASE 3 — CONDITIONING (Days -7 to -1): Patient is admitted to a positive-pressure HEPA-filtered laminar airflow isolation room. A double-lumen or triple-lumen central venous catheter (Hickman or PICC) is placed under ultrasound guidance. The conditioning regimen (MAC or RTC as determined by Pesaro class and organ function) commences. IV Busulfan (with TDM on Day -7 to titrate dose) or Treosulfan is administered. Anti-fungal prophylaxis (Micafungin or Posaconazole), anti-viral prophylaxis (Aciclovir), Pneumocystis prophylaxis (co-trimoxazole, held during conditioning, resumed Day +30), anti-emetics (Ondansetron, Granisetron), and hepatic SOS/VOD prophylaxis (Ursodeoxycholic acid ± Defibrotide in high-risk patients) are initiated. Mucositis monitoring and supportive mouth care begin.

PHASE 4 — STEM CELL INFUSION (Day 0): Donor bone marrow is harvested under general anaesthesia (MSD/haploidentical) or mobilized PBSCs are collected via apheresis. The stem cell product undergoes quality testing (CD34+ cell count target: >3–5×10⁶/kg recipient body weight for PBSC; >2×10⁸ TNC/kg for BM). Infusion is administered intravenously over 1–4 hours via the central catheter under continuous cardiorespiratory monitoring. The patient may experience mild infusion reactions (managed with hydrocortisone, chlorphenamine); cryoprotectant (DMSO) odour is expected if a frozen product is used.

PHASE 5 — ENGRAFTMENT PERIOD (Days +1 to +30): This is the most medically intensive period. Absolute neutrophil count (ANC) nadirs to <0.1×10⁹/L; the patient is at high risk for bacterial and fungal sepsis, CMV reactivation, and haemorrhage. Daily CBC, twice-weekly CMV PCR surveillance (with pre-emptive Ganciclovir or Foscarnet if CMV copies >500–1,000 IU/mL), platelet transfusion support (target >20×10⁹/L or >50×10⁹/L with bleeding), and packed RBC transfusions (irradiated, CMV-negative, leuco-depleted) are administered. Engraftment is defined as ANC >0.5×10⁹/L for 3 consecutive days (typically Day +14 to +21). Chimerism analysis (STR-PCR or SNP array) at Day +30 confirms full donor chimerism (goal: >95% donor).

PHASE 6 — EARLY POST-ENGRAFTMENT & ACUTE GvHD SURVEILLANCE (Days +30 to +100): Patient transitions from isolation to a standard transplant ward room, then to outpatient attendance (with accommodation maintained nearby). Daily to twice-weekly clinical review: LFTs, creatinine, CyA levels (target trough 150–250 ng/mL in the first 3 months), CBC, CMV/EBV PCR, chimerism studies (at Days +30, +60, +100). Acute GvHD (aGvHD) manifests most commonly in skin (maculopapular rash), gut (diarrhoea >500 mL/day), or liver (rising bilirubin). Grade I–II aGvHD is treated with topical steroids or systemic Methylprednisolone (1–2 mg/kg/day); Grade III–IV requires Ruxolitinib (JAK1/2 inhibitor, FDA-approved for steroid-refractory aGvHD) or Extracorporeal Photopheresis (ECP). Graft rejection (mixed or declining chimerism) may require donor lymphocyte infusion (DLI) or second transplant counselling.

PHASE 7 — FIT-TO-FLY ASSESSMENT & DISCHARGE PLANNING (Days +100 to +180): At Day +100, a formal clinical milestone review is conducted: full donor chimerism confirmed, immunosuppression taper initiated (CyA weaned over Months 3–12), no active GvHD above Grade I, no uncontrolled infection, stable haemoglobin (typically 10–13 g/dL on donor RBCs), and platelet count >80×10⁹/L without transfusion support. If criteria are met, international travel clearance is issued. Patients from endemic regions require documented completion of live vaccine deferral schedules (no live vaccines for 24 months post-transplant) and written emergency protocols for the receiving country physician. GAF Healthcare facilitates transfer of complete medical records, Day +100 chimerism reports, current immunosuppression prescription, and a 30-day emergency drug supply.

PHASE 8 — LONG-TERM FOLLOW-UP (Months 6–24+): Immunosuppression (CyA) is fully tapered by Month 9–12 in uncomplicated cases. Chronic GvHD (cGvHD) screening continues at each follow-up visit (NIH Consensus Criteria); manifestations include sicca syndrome, scleroderma-like skin changes, bronchiolitis obliterans, and cholestatic liver disease, treated with Tacrolimus, Mycophenolate, Ibrutinib (for cGvHD refractory disease, FDA-approved), or ECP. Endocrine rehabilitation — thyroid replacement (Levothyroxine), growth hormone therapy in paediatric patients with documented GH deficiency, sex hormone replacement for gonadal failure — is coordinated with the endocrinology team. Iron depletion via therapeutic phlebotomy (once haemoglobin is stably >10 g/dL) or continued oral chelation accelerates resolution of iron overload. GAF Healthcare provides telemedicine coordination between the home country physician and the transplant center for all follow-up visits through Month 24.